Evidence map›Paper›PMID 40113755›Full record

ArticleNature communications2025

Deciphering the dark cancer phosphoproteome using machine-learned co-regulation of phosphosites.

Wen Jiang, Eric J Jaehnig, Yuxing Liao, Zhiao Shi, Tomer M Yaron-Barir, Jared L Johnson, Lewis C Cantley, Bing Zhang

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Wen JiangLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, 77030, USA.
Eric J JaehnigLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-9618-6011
Yuxing LiaoLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-1238-2021
Zhiao ShiLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, 77030, USA.
Tomer M Yaron-BarirMeyer Cancer Center, Weill Cornell Medicine, New York, NY, 10021, USA.ORCID http://orcid.org/0000-0001-6574-7314
Jared L JohnsonDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0003-1802-6527
Lewis C CantleyDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0002-1298-7653
Bing ZhangLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, 77030, USA. bing.zhang@bcm.edu.ORCID http://orcid.org/0000-0001-8676-2425

Funding

Tuberous Sclerosis-Pathway and PathogenesisP01CA120964 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI David J. Kwiatkowski · 2007 to 2026
$35.9M
Role of Phosphoinositides and Protein Kinases in the control of Cancer MetabolismR35CA197588 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEWIS C. CANTLEY · 2016 to 2026
$10.2M
Translating Pediatric Cancer Proteogenomic Data into Biological and Clinical InsightsU24CA271076 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Bing Zhang · 2022 to 2026
$5.0M
Proteogenomics-driven therapeutic discovery in hepatocellular carcinomaR01CA245903 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ZHANG, BING · 2020 to 2024
$1.0M
Illuminating understudied druggable proteins using pan-cancer proteogenomics dataU01CA271247 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ZHANG, BING · 2022 to 2023
$955k
Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RP210027Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RP220050NCI NIH HHS P01 CA120964NCI NIH HHS R01 CA245903NCI NIH HHS R35 CA197588NCI NIH HHS U01 CA271247NCI NIH HHS U24 CA271076U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U24 CA271076, R01 CA245903, U01 CA271247
6 · The paper itself

Abstract

Mass spectrometry-based phosphoproteomics offers a comprehensive view of protein phosphorylation, yet our limited knowledge about the regulation and function of most phosphosites hampers the extraction of meaningful biological insights. To address this challenge, we integrate machine learning with phosphoproteomic data from 1195 tumor specimens spanning 11 cancer types to construct CoPheeMap, a network that maps the co-regulation of 26,280 phosphosites. By incorporating network features from CoPheeMap into a second machine learning model, namely CoPheeKSA, we achieve superior performance in predicting kinase-substrate associations. CoPheeKSA uncovers 24,015 associations between 9399 phosphosites and 104 serine/threonine kinases, shedding light on many unannotated phosphosites and understudied kinases. We validate the accuracy of these predictions using experimentally determined kinase-substrate specificities. Through the application of CoPheeMap and CoPheeKSA to phosphosites with high computationally predicted functional significance and those associated with cancer, we demonstrate their effectiveness in systematically elucidating phosphosites of interest. These analyses unveil dysregulated signaling processes in human cancer and identify understudied kinases as potential therapeutic targets.

Indexed as

Machine LearningNeoplasmsPhosphoproteinsProteomeProteomicsHumansPhosphorylationSignal TransductionSubstrate SpecificityPhosphoproteinsProteome

Identifiers

PMID40113755
PMCPMC11926083

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.